Gilead abandons filgotinib for rheumatoid arthritis in U.S. – Reuters India

Gilead abandons filgotinib for rheumatoid arthritis in U.S. – Reuters India

Gilead Sciences Inc said on Tuesday it had decided not to pursue the U.S. Food and Drug Administration’s approval of its experimental rheumatoid arthritis treatment, filgotinib, following a meeting with the health regulator.

Read More…

You May Also Like